Bank of America
ALXO icon

Bank of America’s ALX Oncology ALXO Stock Holding History

Bank of America’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Sell
76,032
-501,751
-87% -$898K ﹤0.01% 5451
2026
Q1 		$1.16M Buy
577,783
+45,938
+9% +$87.5K ﹤0.01% 4445
2025
Q4 		$601K Buy
531,845
+1,017
+0.2% +$1.54K ﹤0.01% 4816
2025
Q3 		$971K Sell
530,828
-504,299
-49% -$437K ﹤0.01% 5347
2025
Q2 		$430K Sell
1,035,127
-416,651
-29% -$210K ﹤0.01% 5791
2025
Q1 		$904K Buy
1,451,778
+416,452
+40% +$500K ﹤0.01% 5293
2024
Q4 		$1.73M Buy
1,035,326
+860,703
+493% +$1.32M ﹤0.01% 4573
2024
Q3 		$318K Buy
174,623
+133,613
+326% +$497K ﹤0.01% 5767
2024
Q2 		$247K Sell
41,010
-6,145
-13% -$75.6K ﹤0.01% 5774
2024
Q1 		$526K Sell
47,155
-17,601
-27% -$247K ﹤0.01% 5323
2023
Q4 		$964K Buy
64,756
+13,008
+25% +$123K ﹤0.01% 5011
2023
Q3 		$248K Buy
51,748
+24,447
+90% +$133K ﹤0.01% 5767
2023
Q2 		$205K Buy
27,301
+1,896
+7% +$12.4K ﹤0.01% 5808
2023
Q1 		$115K Sell
25,405
-177,669
-87% -$1.35M ﹤0.01% 6200
2022
Q4 		$2.29M Buy
203,074
+180,868
+815% +$2.03M ﹤0.01% 4124
2022
Q3 		$213K Buy
22,206
+5,332
+32% +$62.1K ﹤0.01% 5934
2022
Q2 		$136K Sell
16,874
-41,807
-71% -$455K ﹤0.01% 6320
2022
Q1 		$992K Sell
58,681
-10,644
-15% -$182K ﹤0.01% 5269
2021
Q4 		$1.49M Buy
69,325
+62,419
+904% +$2.69M ﹤0.01% 4846
2021
Q3 		$509K Buy
6,906
+999
+17% +$66.6K ﹤0.01% 5625
2021
Q2 		$323K Buy
5,907
+2,732
+86% +$163K ﹤0.01% 5751
2021
Q1 		$233K Sell
3,175
-3,935
-55% -$310K ﹤0.01% 5921
2020
Q4 		$613K Sell
7,110
-1,400
-16% -$84.2K ﹤0.01% 4862
2020
Q3 		$321K Buy
+8,510
New +$334K ﹤0.01% 5014

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Bank of America's ALXO Position: Q2 2026 in Review

Bank of America reduced its ALX Oncology (ALXO) stake by 87% in Q2 2026, selling an estimated $898K and leaving 76,032 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #5451.

Bank of America first reported a position in ALXO in Q3 2020 and has held it in 24 quarters since. The position peaked at $2.29M in Q4 2022. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Bank of America held 76,032 shares of ALX Oncology worth $157K as of Q2 2026.
  • Bank of America sold 501,751 ALX Oncology shares in Q2 2026, an estimated $898K.
  • ALX Oncology made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #5451 holding.
  • Bank of America first reported a position in ALX Oncology in Q3 2020 and has held it in 24 quarters since.
  • Bank of America's ALX Oncology position peaked at $2.29M in Q4 2022.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.